Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4367 USD | -0.07% | +26.03% | +47.24% |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+47.24% | 56.09M | C | ||
-1.65% | 103B | B+ | ||
+6.75% | 101B | B+ | ||
+5.71% | 23.07B | B | ||
-12.60% | 22.23B | B+ | ||
-9.70% | 18.05B | A- | ||
-39.98% | 17.18B | A- | ||
-10.17% | 16.94B | B | ||
+6.12% | 14.07B | C+ | ||
+35.47% | 12.35B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CLNN Stock
- Ratings Clene Inc.